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Abstract
During the past decade, three proteins that possess the capability of packaging glutamate into presynaptic vesicles have been
identiﬁed and characterized. These three vesicular glutamate transporters, VGLUT1–3, are encoded by solute carrier genes
Slc17a6–8. VGLUT1 (Slc17a7) and VGLUT2 (Slc17a6) are expressed in glutamatergic neurons, while VGLUT3 (Slc17a8)i s
expressed in neurons classically deﬁned by their use of another transmitter, such asacetylcholine and serotonin. As glutamate is
both a ubiquitous amino acid and the most abundant neurotransmitter in the adult central nervous system, the discovery of the
VGLUTs made it possible for the ﬁrst time to identify and speciﬁcally target glutamatergic neurons. By molecular cloning
techniques, different VGLUT isoforms have been genetically targeted in mice, creating models with alterations in their
glutamatergic signalling. Glutamate signalling is essential for life, and its excitatory function is involved in almost every
neuronal circuit. The importance of glutamatergic signalling was very obvious when studying full knockout models of both
VGLUT1 and VGLUT2, none of which were compatible with normal life. While VGLUT1 full knockout mice die after
weaning, VGLUT2 full knockout mice die immediately after birth. Many neurological diseases have been associated with
altered glutamatergic signalling in different brain regions, which is why conditional knockout mice with abolished VGLUT-
mediated signalling only in speciﬁc circuits may prove helpful in understanding molecular mechanisms behind such
pathologies. We review the recent studies in which mouse genetics have been used to characterize the functional role of
VGLUT2 in the central nervous system.
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Glutamate and vesicular glutamate
transporters
For 25 years, glutamate has been accepted as the most
abundant excitatory neurotransmitter in the adult
central nervous system (1), and glutamatergic neu-
rons and glutamate-mediated excitatory signalling are
implicated in all neuronal circuits of the central ner-
vous system (2). Glutamate is necessary for brain
function, and several diseases have been associated
with defective or altered glutamate signalling, includ-
ing Parkinson’s disease, schizophrenia, Alzheimer’s
disease, amyotrophic lateral sclerosis (ALS), and
depression (3–5). Increased knowledge of gluta-
matergic neurotransmission should therefore prove
helpful in the treatment of several such disorders.
As glutamate is a ubiquitous amino acid, the study
of glutamatergic neurotransmission was for a long
time hampered by the lack of markers speciﬁc for
glutamate signalling neurons. Most of the current
knowledge of glutamatergic neurotransmission is
derived from pharmacological studies and gene
targeting studies of the postsynaptic machinery,
including both the cytoplasmic membrane trans-
porters and the different kinds of glutamate receptors.
However, none of these studies have directly
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signalling neuron itself. A fundamental step forward
for the research ﬁeld around glutamate came with
the recent identiﬁcation that three members of the
solute carrier family, Slc17a6–8, act as vesicular glu-
tamate transporters (and were hence named
VGLUT1, 2, 3). Their discovery has enabled proper
identiﬁcation of glutamate signalling neurons and
studies of glutamatergic neurotransmission (6–8).
VGLUT1 and VGLUT2 are considered the most
reliable markers for glutamatergic neurons and rep-
resent important targets for the study of excitatory
neurons in vivo. Their expression pattern is to a large
extent complementary, with VGLUT1 mainly
expressed in the cerebral and cerebellar cortex and
hippocampus, and VGLUT2 mainly expressed in
deeper brain regions including the thalamus and
the brainstem (for an example of Vglut2 mRNA
expression, see Figure 1, which was produced in
our laboratory by digoxigenin-labelled in situ
hybridization on vibratome-sliced sections) (7,9,10).
The spatial distribution is not absolute, however;
VGLUT2 is for example expressed in subpopulations
of the cerebral cortex and hippocampus throughout
life. There is also a temporal difference in VGLUT
isoform expression, where VGLUT2 is most abun-
dantly expressed during embryonic and early postna-
tal development, whereafter VGLUT1 becomes the
dominating isoform in certain brain areas (11).
With the identiﬁcation of the VGLUTs, it became
possible to genetically alter glutamate signalling in the
entire brain, or in speciﬁc brain circuits, and study the
phenotype of these alterations in vivo. For example,
the switch from VGLUT2 to VGLUT1 expression
was observed in vivo by both Fremeau et al. and
Wojcik et al. in 2004, when they genetically deleted
VGLUT1 expression in mice using full knockout
strategies (12,13). The Vglut1
-/- mice survived 2 weeks
after birth, but as the VGLUT1 expression increased
during the third postnatal week in the wild-type
animals, the Vglut1
-/- mice started to die. These
studies showed that VGLUT1 is not essential for
life-supporting mechanisms immediately ex utero,a
ﬁnding that was received with a certain degree of
surprise (14). That glutamatergic signalling is
required for new-born life was without doubt, and
it was speculated that VGLUT2 may be the essential
VGLUT. VGLUT2 is indeed expressed in several
brainstem nuclei involved in control of both respira-
tion and cardiovascular function (15,16) and is
thereby heavily implicated in life-supporting mechan-
isms. However, VGLUT2 is broadly expressed in the
brain and spinal cord and is likely to play various roles
in many different neuronal circuitries, roles which are
now, with the use of gene targeting, becoming
increasingly known. Here we review the recent studies
of VGLUT2 mouse genetics, a research ﬁeld which is
fairly new but which has already implicated VGLUT2
in diverse functions, some which were to a certain
degree expected and some a bit more unexpected.
Knock-out strategies
Molecular biology and cloning strategies have
enabled the possibility to unravel the role of
VGLUT2-dependent glutamate signalling in speciﬁc
neuronal circuits. In the research ﬁeld of VGLUT2
mouse genetics so far, both full gene targeting (in
which the gene is dysfunctional from start) and
conditional gene targeting (in which the gene can
be inactivated in a spatio-temporally restricted
manner using the so-called Cre/LoxP system) have
been utilized. We describe these techniques brieﬂy
in Figure 2. For a more extensive review on the Cre/
LoxP system, see Nagy’s excellent publication (17).
We have chosen to present the VGLUT2 mouse
Bregma 1.34 mm Bregma -1.46 mm Bregma -3.28 mm
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Figure 1. In situ hybridization for Vglut2 on free-ﬂoating coronal adult mouse brain sections showing the expression pattern at three different
bregma levels. Vglut2 mRNA is detected by blue labelling and is seen in the piriform cortex in A (bregma 1.34 mm); in the thalamus,
hypothalamus, piriform cortex, and retrosplenial group of the medial cortex in B (bregma 1.46 mm); and in many cell groups in the
brain-stem, including the geniculate and mammillary nuclei in C (bregma 3.28 mm).
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the deletion, i.e. full knockout studies come ﬁrst,
followed by conditional knockout studies, in
which the deletion is complete in speciﬁcally
selected neurons, and lastly heterozygote studies are
presented, in which the entire organism has a
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Figure 2. A: Full knockout models can be generated by homologous recombination between the wild-type allele and a targeting construct. The
targeting construct lacks one or more exons of the gene, usually in combination with some selection sites. The result after homologous
recombination is an allele lacking one or more exons, and which will produce a non-functional mRNA. B: Conditional knockouts are made in
several steps, where ﬁrst a targeting construct containing one LoxP site on each side of the exons to be deleted is combined with the wild-type
locus through homologous recombination. Second, when mice carrying the allele with ‘ﬂoxed’ (i.e. ﬂanked by LoxP sites) exons are crossed
with mice expressingthe Cre recombinase, the ﬂoxed exons are deleted resulting in a gene producing non-functional mRNA. C: Depending on
which promoter that drives the Cre expression, the ﬂoxed gene—in this case Vglut2—can be deleted in speciﬁc tissues only. As schematically
illustrated here, Vglut2lox mice (ﬂoxed Vglut2 in all cells is illustrated with bright grey dots) mated with Cre mice, where Cre is driven by
forebrain or cerebellum-speciﬁc promoters (dark grey dots in upper and lower panels, respectively) will result in different conditional knockout
mice where Vglut2 expression is speciﬁcally deleted in the Cre-expressing regions (illustrated by black dots).
Genetic inactivation of VGLUT2 in the mouse 13reduction, but not complete deletion, of VGLUT2
expression.
Full knockout studies
In 2006, the ﬁrst two studies of VGLUT2 gene
targeting in the mouse were published. Our group,
as well as that of Moechars and co-workers, both
made full knockout studies, although by using differ-
ent gene targeting strategies. Moechars et al. pro-
duced a mouse model where VGLUT2-dependent
glutamate signalling was inhibited by a complete
targeted deletion of the Vglut2 gene (18). This dele-
tion was made by the knockout strategy described
in Figure 1A, where exon 2 was deleted by homolo-
gous recombination, leading to a disrupted open
reading frame and a premature stop codon. Mice
homozygous for the Vglut2 deletion were, contrary
to the Vglut1
-/-, not viable at birth, and Western blot
analysis of brain homogenates revealed a complete
lack of VGLUT2 protein, while quantitative reverse
transcriptase-PCR (RT-PCR) showed some residual
VGLUT2 mRNA expression. Interestingly, this
complete knockout of VGLUT2 was not compen-
sated for by an increase in VGLUT1 levels, also
shown by Western blot analysis. As the distribution
of VGLUT1 and 2 differs between brain regions, the
authors performed electrophysiological studies on
cells isolated both from the hippocampus (with
high VGLUT1 expression) and the thalamus (with
high VGLUT2 expression) from wild-type and
Vglut2
-/- mice respectively. These studies revealed a
95% reduction in evoked glutamate response in tha-
lamic neurons from Vglut2
-/- mice, while hippocampal
neurons functioned normally. Since the homozygotes
were not viable, behavioural analyses were performed
on mice heterozygous for the VGLUT2 deletion
(Vglut2
+/-). These studies are described in the section
for heterozygote studies below.
In our case, the loss of VGLUT2 was achieved
through a conditional approach using the Cre/LoxP
system (19). We generated our Vglut2
ﬂox/ﬂox mice by
insertion of one LoxP site upstream of exon 4 of the
mouse Vglut2 genomic sequence and one LoxP site
downstream of exon 6. Full knockout mice were
obtainedbymatingoftheVglut2
ﬂox/ﬂoxmicewithphos-
phoglycerate kinase I promoter (PGK)-Cre mice (20).
None of the full knockout mice survived after birth,
and the cyanotic appearance of the mice prompted us
to focus on respiratory activities. Histological analyses
revealed a complete lack of VGLUT2 protein but no
gross malformations in the brain. However, lung
alveoli were reduced in the Vglut2
ﬂox/ﬂox;PGK-Cre mice
as if non-inﬂated. When fetuses were surgically
Table I. A summary of the different Vglut2 inactivation events, the cell population they affect and the phenotypes they give rise to.
Type of Vglut2
inactivation Cre-promoter Name
Region
affected Major phenotype Ref.
Full knockout,
conditional strategy
PGK Vglut2
ﬂox/ﬂox;PCre All cells Lethal phenotype. No
activity in respiratory CPG
while normal activity of
locomotor CPG
(19)
Conditional knockout SF-1 Sf1-Cre,Vglut2
ﬂox/ﬂox VMH Defective counterregulatory
responses to hypoglycaemia
(26)
Conditional knockout CamKII Vglut2
ﬂox/ﬂox;CaMKII-Cre Cortex,
amygdala
Hyperactivity, reduced
memory and prepulse
inhibition, schizophrenia-
like behaviour. Effect on the
dopamine system
(29)
Heterozygous full
knockout,
conditional strategy,
crossed with ALS mouse
model
PGK Sod1
G93A;Vglut2
ﬂox/+ All cells Rescued motor neuron
viability
(46)
Full knockout Vglut2
-/- All cells Lethal phenotype. No
VGLUT2 protein
expression and no up-
regulation of VGLUT1
(18)
Heterozygous through
full knockout strategy
Vglut2
+/- All cells Impaired acquisition of
neuropathic pain; Increased
sensitivity to PTZ clonic
seizures.
(41); (43)
CPG = central pattern generator, ALS = amyotrophic lateral sclerosis, VMH = ventromedial hypothalamus, PTZ = pentylenetetrazol
14 Å. Wallén-Mackenzie et al.delivered at embryonic day 18.5 (E18.5), wild-type
and heterozygote siblings immediately initiated
breathing and showed a stable breathing behaviour.
In contrast, no respiratory behaviour was observed in
the full knockout embryos.
The respiratory central pattern generator (CPG)
belongs to the better characterized CPGs, although
before the production of VGLUT2 knockout mice it
had been somewhat difﬁcult to pin-point the role of
glutamate signalling in this circuit. Since no respira-
tory behaviour was observed in the Vglut2
ﬂox/ﬂox;PCre
mice, we were interested in further investigating the
respiratory CPG and in particular the pre-Bötzinger
complex (PBC) which is a network pacing the respi-
ratory rhythm. The PBC is located in the rostroven-
trolateral medulla, and its neurons are dependent
on activation of glutamate receptors (N-methyl
D-asperate (NMDA) and non-NMDA) to depolarize.
By the targeted deletion of VGLUT2, we abolished
the presynaptic release of glutamate and could show
that this release was crucial to initiate the respiratory-
related rhythm generation of the PBC. When fetuses
were placed in a plethysmographic chamber to record
ventilation, none of the Vglut2
ﬂox/ﬂox;PCre showed any
breathing behaviour, consistent with their malformed,
defective lungs, while wild-type mice breathed at a
normal frequency. To resolve the mechanisms behind
this failed breathing initiation, we performed electro-
physiology studies of brainstems from surgically deliv-
ered embryos. In contrast to wild-type preparations,
recordings on brainstems from mutants showed no
spontaneous rhythmic activity of the hypoglossal
nerve root (12n). To investigate rhythm generation
from the PBC, medullar slices were prepared and
analysed through calcium imaging and extracellular
electrophysiological recordings. For wild-type slices
from E16.5 embryos, a spontaneous rhythmic
activity was observed as changes in calcium-induced
ﬂuorescence, which as previously observed by others
(21) could be reversed by blocking a-amino-3-
hydroxyl-5-methyl-4-isoxazole-propionate (AMPA)/
kainate receptors. However, for slices from the
Vglut2
ﬂox/ﬂox;PCre, no rhythmic activity could be
observed. On a single-cell level, the fast AMPA/
kainite-mediated synaptic events recorded in wild-
type cells by whole-cell voltage clamp experiments
were not observedinVglut2
ﬂox/ﬂox;PCrecells,suggesting
that the lack of VGLUT2 mediates a selective
absence of such fast synaptic events. Interestingly,
thorough morphological and histological studies
revealed no effect on the structural and cellular orga-
nization of the brainstem nuclei involved in respira-
tion. Electron microscopy analyses of synaptic vesicles
in Vglut2
ﬂox/ﬂox;PCre mice showed a malformation of
vesicles in asymmetric synapses in areas ‘normally’
rich in VGLUT2, though vesicles at symmetric syn-
apses appeared morphologically normal. Taken
together, by genetically eliminating VGLUT2 in
mice, we could demonstrate the crucial need of
VGLUT2-mediated glutamatergic signalling within
the PBC to initiate respiratory behaviour already at
the embryonic state. We also analysed the locomotor
CPG, which has been suggested to be dependent on
glutamatergic signalling mediated by VGLUT2 (22–
25);however,wecouldnotﬁndevidencethatthisisthe
case. Thus, the respiratory CPG and the locomotor
CPG do not seem to have a VGLUT2-dependency
in common.
Conditional knockout studies
The hypothalamus
The ﬁrst study using a cell type-speciﬁc Cre to delete
VGLUT2 function was published by Tong and col-
laborators in 2007 (26). These authors generated
Vglut2
ﬂox/ﬂox mice by ﬂanking exon 2 of the mouse
Vglut2 genomic sequence with LoxP sites, which
resulted in a null allele as exon 1 only contains about
5% of the coding sequence of Vglut2 and as the
reading frame is disrupted. The authors were inter-
ested in evaluating the role of VGLUT2 in ventro-
medial hypothalamic (VMH) neurons, which are
predominantly glutamatergic and previously were
shown to express VGLUT2 (27). The VMH is
believed to play a role in the neurocircuitry important
for detection of hypoglycaemia and the subsequent
counterregulatory responses that are activated to
ensure that the brain receives adequate glucose sup-
ply. The counterregulatory measures that occur upon
low blood glucose levels are the following: insulin
secretion, glucagon secretion, epinephrine secretion
(if needed), and, lastly, stimulation of food intake.
While insulin secretion is believed to be primarily a
response of pancreatic beta cells, the other three
responses are primarily driven by the brain. The exact
nature of the neurocircuitry underlying these
responses and the mechanisms of its function are
not known but are important to unravel, not least
as the counterregulatory responses are dysfunctional
in patients that suffer from diabetes.
The brain contains two kinds of glucose-sensing
neurons: ‘glucose-excited’ neurons that increase their
ﬁring rate as glucose levels rise, and ‘glucose-
inhibited’ neurons that decrease their ﬁring as
glucose levels fall. The decreased activity of the
‘glucose-excited’ neurons, the increased activity of
the ‘glucose-inhibited’ neurons action, input from
peripheral blood glucose sensors, as well as a
combination of the three, are suggested as the means
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glucose-sensing neurons are abundant in parts of the
hypothalamus, including the VMH, the lateral hypo-
thalamus, and the arcuate nucleus, and in the hind-
brain. The presence of glucose-sensing neurons
implicates the VMH in the neurocircuitry behind
detection of hypoglycaemia and the adequate coun-
terresponses. Tong and collaborators set out to test
directly the hypothesis that the glutamatergic neu-
rons of the VMH play a role in this neurocircuitry by
inactivating VGLUT2 speciﬁcally in these neurons.
For this, they crossed their SF-1-Cre transgenic mice
(28), which express Cre exclusively in the VMH, to
their Vglut2
ﬂox/ﬂox mice and analysed the offspring. In
their ﬁrst experiment, they performed electro-
physiological recordings on autaptic cultures of
steroidogenic factor-1 (SF-1)neurons and could
show two ﬁndings: 1) most of the SF-1 neurons
are glutamatergic while a smaller proportion is
GABAergic, and 2) glutamate release is disrupted
in their Vglut2
ﬂox/ﬂox;SF1-Cre mice (no excitatory post-
synaptic currents (EPSCs) were detected in the knock-
out neurons). Having conﬁrmed this, the authors
analysed features related to feeding and blood glucose
levels. Tong et al. found that the knockout mice had
normal body-weight whenfeda standardchowdietbut
developed some increased body-weight compared to
controls when fed a high-fat, high-sucrose diet. The
authors concluded that release of glutamate from the
SF-1 neurons plays a small role in regulating energy
balance upon fat-feeding but not in standard feeding.
The mice were then subjected to fasting for
24 hours, whereupon blood glucose, insulin, and
glucagon were measured. The ﬁndings were quite
striking. While insulin levels were similar in the
knockout and control groups, blood glucose and
glucagon levels were lower in the knockouts. The
pancreatic hormone glucagon works on the liver
and stimulates break-down of glycogen to glucose
(glycogenolysis) as well as synthesis of glucose from
other sources (gluconeogenesis). Gluconeogenesis
can be detected in liver-derived mRNA as it leads
to transcriptional regulation of gluconeogenic
enzymes and a co-activator, PGC-1a. While these
liver-expressed genes were transcriptionally increased
in the controls, no increased gene expression was
observedin the knockouts. These experiments showed
that the impaired glucose homeostasis in the knockout
mice was mediated by failure to increase blood glu-
cagon levels which was followed by failure to induce
expression of gluconeogenic genes in the liver.
An acute injection of insulin revealed that the
Vglut2
ﬂox/ﬂox;SF1-Cre mice suffered a more substantial
fall in blood glucose than did the controls, a greater
degree of hypoglycaemia that was followed by
impaired glucagon response. The authors then
performed hypoglycaemic clamp studies, where
hypoglycaemia was induced by infusion of human
regular insulin and sustained at similar levels in a
controlled way for 60–90 minutes during which sam-
ples for epinephrine and glucagon were taken. This
analysis showed that the knockout mice required
higher rates of glucose infusion to keep the clamp,
a ﬁnding consistent with decreased rates of glucagon
production, which was also detected. In addition, a
hypoglycaemia-induced increase in epinephrine
observed in the controls was not detected in the
knockout mice. The authors then treated the mice
with 2-deoxyglucose (2-DG) by injection into the
third ventricle, which in the controls led to brain-
mediated increased blood glucose levels, plasma
glucagon levels, and increased gene expression of glu-
coneogenic genes in the liver. None of these res-
ponses were observed in the Vglut2
ﬂox/ﬂox;SF1-Cre mice.
Together, these experiments showed that the counter-
regulatory responses to hypoglycaemia are deﬁcient in
theVglut2
ﬂox/ﬂox;SF1-Cremice,andduetotheveryselec-
tive targeting event of Vglut2 in this mouse model the
authors were able to conﬁdently suggest that the effects
are mediated via loss of glutamate release in the VMH.
The cortex and amygdala
In the beginning of 2009, we published our ﬁrst paper
where we had used a region-speciﬁc Cre mouse to
delete VGLUT2 function in speciﬁc neurons (29).
Based on gene expression analysis, it is clear that the
majority of neurons in the postnatal cortex and hip-
pocampus predominantly express VGLUT1
(7,9,10,15,30–32). However, a few cells in discrete
regions of the cortex, such as in the retrosplenial
group and the piriform cortex, as well as neurons
in layers III and V/VI, do express certain levels of
VGLUT2, as does the subiculum of the hippocam-
pus. We were interested in analysing the functional
role of these neurons and used the CamKII-Cre
mouse to target these neurons in our Vglut2
ﬂox/ﬂox
mice. The CamKII-Cre mouse has been carefully
analysed and the Cre recombinase has been shown
to be expressed in the cortex, hippocampus, striatum,
and amygdala (33). VGLUT2 is not expressed in the
striatum, but is expressed in a subset of the amygda-
loid nuclei. Although we had not anticipated a major
phenotype, it became evident when ear-tagging the
ﬁrst litters of Vglut2
ﬂox/ﬂox;CamKII-Cre mice after wean-
ing that they had a clearly noticeable behaviour, in
that the mice moved around a lot and instead of trying
to avoid the caretaker’s hand rather turned towards
the hand. After having conﬁrmed the loss of Vglut2
mRNA in the expected cortical areas and amygdaloid
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target areas of these neurons, we set out to analyse
the behaviour of the mice using validated behavioural
paradigms. Based on our initial observations, we ﬁrst
analysed anxiety-related behaviour in the Elevated
Plus Maze (EPM) and found an increased frequency
and duration in the open arm, especially in the outer
part of this arm, in the knockouts compared to the
controls. In addition to suggesting a decreased anx-
iety-related behaviour, analysis of the total frequency
in the different compartments showed that the knock-
out mice were signiﬁcantly more active than the
controls. We then turned to the more sensitive
Multi-Concentric Square Field (MCSF) (34),
developed by Erika Roman and Bengt Meyerson
at the Biomedical Center in Uppsala, in which
the mice are allowed freely to explore a challenging
environment. In addition to conﬁrming the hyper-
activity of the Vglut2
ﬂox/ﬂox;CamKII-Cre mice, the
MCSF also revealed that the knockout mice to a
lesser extent avoided the open area and that they spent
less time in the dark corner and more time in areas
associated with risk assessment and risk-taking. The
altered emotional behaviour observed in the EPM
and MCSF was followed by social behaviour analyses
to assess the social competence of the mice. The
Vglut2
ﬂox/ﬂox;CamKII-Cre mice showed increased domi-
nance but also increased interaction with their coun-
terparts. We also analysed cognitive functions by
using the Morris Water Maze. While showing no
defects in the learning process using this paradigm,
the Vglut2
ﬂox/ﬂox;CamKII-Cre mice did display a reduc-
tion in spatial memory function, when a probe test
was performed 6 days after the last training day.
Cognitive deﬁciency, such as decreased memory
function, is one criterion for schizophrenia, a human
disorder also characterized by positive symptoms such
as hallucinations and delusions, and negative symp-
toms such as blunted emotional expression and
altered social behaviour. While hallucinations and
delusions cannot be analysed in animal models of
this disease, hyperactive behaviour has been classi-
ﬁed as a positive symptom of schizophrenia-like
behaviour. Positive and negative symptoms together
with cognitive deﬁciency are also criteria for schizo-
phrenia-like behaviour in animal models of the
disease. The Vglut2
ﬂox/ﬂox;CamKII-Cre mice fulﬁla l l
these three groups of criteria for schizophrenia-
like behaviour. In addition, the Vglut2
ﬂox/ﬂox;CamKII-Cre
mice display altered prepulse inhibition as well as an
effect on dopaminergic signalling, features consid-
ered as cardinal symptoms of schizophrenia and
schizophrenia-like behaviour. We suggest that the
Vglut2
ﬂox/ﬂox;CamKII-Cre mice may function as a gene-
tic hypoglutamate model of schizophrenia-like
behaviour and may be of use for validation of new
psychopharmacological drugs.
Heterozygote studies
The Vglut2
-/- mice are models of completely absent
VGLUT2-mediated glutamate signalling, either in
the whole brain or in speciﬁc neuronal circuits. There
is evidence that alterations in the numberof VGLUT2
molecules also affect the glutamate signalling prop-
erties (18,35,36) and that such an alteration in both
gene expression and protein levels are associated with
disease (5,37–39). One theory is that the number of
VGLUT molecules available at the presynapse is in
direct correlation with the amount of glutamate pack-
aged into the vesicles, which in turn affects the efﬁ-
ciency of the signalling itself. This dose-dependence
can be studied using heterozygous knockout mice,
having their VGLUT2 expression reduced by approx-
imately 50%. Moechars and co-workers used their full
knockout model, described above, for such studies
and observed through electrophysiological studies on
cultured neurons that cells from homozygous mice
had almost no residual excitatory transmission, while
cells from heterozygous mice had a functional signal-
ling, although reduced by 25% compared to wild type,
measured as the postsynaptic response to one single
vesicle fusion—the quantal size. The quantal size
varies depending on several parameters, including
concentration of glutamate in the vesicle (40), which
is why a reduction in the number of VGLUT2 pro-
teins is likely to cause the reduced postsynaptic
response by less glutamate transport into the vesicles
and thus a reduced ﬁlling state. Conversely, over-
expression of VGLUTs has been demonstrated to
increase quantal size (36).
Thalamus and pain
To investigate the phenotype caused by the 50%
reduction in VGLUT2 protein levels in heterozygotes
(18), Moechars et al. compared Vglut2
+/- to wild-type
mice in a battery of behavioural tests. While there was
no difference between the genotypes in motor func-
tion, learning and memory, acute nociception, or
inﬂammatory pain, they had alterations in tests indic-
ative of neuropathic pain. Acute nociception was
unchanged in Vglut2
+/- mice, which indicates that
the glutamatergic signalling in the nociceptive path-
way is independent of VGLUT2, unaffected by the
50% decrease in VGLUT2 levels, or compensated by
an increased peripheral VGLUT1 expression. The
same seems to be the case for inﬂammatory pain,
as tested by the formalin test which involves gluta-
matergic sensitization in the periphery and spinal
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neuropathic pain in heterozygous mice supports the
involvement of VGLUT2-dependent glutamate sig-
nalling from the thalamus in such responses (18).
The same model was further studied by the same
group, and it was compared to heterozygous Vglut1
knockout mice in a study using additional behavioural
pain analyses (41). Vglut1
+/- mice displayed no altera-
tions in neuropathic pain tests, whereas Vglut2
+/- did
also in this study. Here, two additional tests of nerve
injury were included—spared nerve injury (SNI) and
chronic constriction injury (CCI). After surgery, mice
were tested using the von Frey set-up to assess
mechanical sensitivity and the writhing test with ace-
tone exposure to assay for chemical nociception. All
mice showed a lowered threshold in von Frey’sa sa
response to the mechanical allodynia caused by the
SNI, except the Vglut2
+/- mice which did not respond
to the injury. The same was observed after acetone
exposure, where Vglut2
+/- mice failed to develop a
cold allodynia-like response to injury. For the CCI
test of mechanical allodynia, Vglut2
+/- mice did not
differ from controls in von Frey’s test but did respond
to acetone spray, however to a lesser extent than did
wild-type mice. Thus, Vglut2
+/- mice fail to display
typical signs of neuropathic pain. Both these studies,
where different aspects of pain were investigated,
converge on VGLUT2-dependent signalling—and
not VGLUT1—as being an important player in medi-
ating neuropathic pain responses, a ﬁnding of impor-
tance not least for drug development in the pain area.
Hippocampus and epilepsy
Alterations in glutamatergic signalling has, as
described above, been implicated in several diseases
and among them epilepsy. For example, studies in
Mongolian gerbils demonstrated an increased
VGLUT2 immunoreactivity in parts of the hippocam-
pus in epileptic seizure-prone gerbils (42), which
could be related to a hyperexcitability in these ani-
mals. These studies prompted Schallier and co-work-
ers to study epileptic-like behaviour on their Vglut2
+/-
mice (43). Epileptic seizures can be induced exper-
imentally by administration of pentylenetetrazol
(PTZ), which in rodents induces different types of
seizures at different doses. The seizures can be
recorded in electroencephalograms (EEGs). Vglut2
+/-
mice, from the same mouse line as used for the pain
studies described above (18,41), needed lower doses
of PTZ than did wild-type litter-mates to induce the
ﬁrst myoclonic twitch as well as the fore-limb clonus,
while the threshold dose for tonic hind limb exten-
sion and the lethal dose did not differ signiﬁcantly
between groups. Importantly, the Vglut2
+/- mice had
no alterations in base-line EEG, and thus their 50%
reduction in VGLUT2 levels did not seem to induce
spontaneous seizures. This enhanced sensitivity to
clonicepilepticseizuresinVglut2
+/-micecould,accord-
ing to Schallier et al., be explained by alterations in the
thalamocortical circuitry caused by their 50% reduc-
tion of VGLUT2 in e.g. thalamus. Projections going
from thalamus to the cortex are mainly glutamatergic,
andthispathwayalsosendscollateralexcitatoryprojec-
tions to the reticular thalamic nucleus (RTN). The
neurons of RTN then send inhibitory GABAergic sig-
nals back to the thalamocortical neurons. These neu-
rons are also intensively activated by PTZ (44). In
Vglut2
+/- mice this leads to an increased inhibition
from the RTN, which further decreases the excitatory
outputofthethalamocorticalneurons.Accordingtothe
authors, this altered signalling could explain their
enhanced sensitivity to PTZ.
Motor neurons and amyotrophic lateral sclerosis
Glutamate is the most abundant excitatory neuro-
transmitter, and its presence in the extracellular space
must be tightly regulated as excessive release of glu-
tamate into the synaptic cleft can induce excitotoxicity
and death of the postsynaptic neuron. This excito-
toxicity has been suggested to be involved in the
pathogenesis of amyotrophic lateral sclerosis (ALS),
a disease where motor neurons gradually die leading
to paralysis of the patient. The only approved drug to
treat ALS reduces excitotoxicity by reducing gluta-
matergic signalling (45). A decrease in glutamatergic
signalling could prove beneﬁcial for survival of motor
neurons and halting the progression of ALS. To test
this hypothesis, we crossed our Vglut2
ﬂox/+ mice with a
Sod1
G93A mouse, a well characterized model for ALS
which has previously been demonstrated to show an
ALS-like phenotype with progressive loss of motor
neurons. In this way, we generated an ALS mouse
model with attenuated VGLUT2-dependent gluta-
matergic signalling (46). Sod1
G93A;Vglut2
ﬂox/+ mice
did have reduced VGLUT2 protein levels in their
spinal cord, not compensated by an increase in
VGLUT1, but had no alterations in disease onset,
life-span, or weight loss compared to Sod1
G93A;
Vglut2
+/+ litter-mate mice. However, immunohisto-
chemical analyses of spinal cord sections revealed that
a reduction in VGLUT2 levels increased viability of
larger neurons—most likely motor neurons—of the
spinal cord. In addition, expression studies of motor
neuron-speciﬁc markers, vesicular acetylcholine
transporter and the high afﬁnity choline transporter,
demonstrated that motor neurons in the lumbar
spinal cord were partly spared from degeneration
by reduced VGLUT2 expression in Sod1
G93A;
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ﬂox/+ mice. To investigate if these rescued
neurons still were connected to the muscle we inves-
tigated neuromuscular junctions (NMJs) in tibialis
anterior. In control mice, almost all NMJs were
innervated by motor neurons, an innervation that
was markedly reduced in the Sod1
G93A;Vglut2
ﬂox/+
mouse.Thus,intheSod1
G93A;Vglut2
ﬂox/+model,parts
ofthereducedNMJinnervationcouldberescued.This
indicated to us that the rescued motor neuron cell-
bodies in the spinal cord were in fact connected to the
muscle. Interestingly, cholinergic motor neurons in
two cranial nuclei (VII and XII) of the brainstem
responded differently to reduced VGLUT2. In the
VIIth cranial nucleus, we observed a complete rescue
of motor neurons by reducing VGLUT2 levels, while
the XIIth cranial nucleus was completely unaffected
by the disease and no cell loss was observed.
By creating this heterozygotic Vglut2
ﬂox/+ mouse
model we were able to evaluate a putative role for
VGLUT2 in ALS. This study shows that glutamate
excitotoxicity is part of the ALS disease progression
and that different motor neuron populations have
different susceptibility for this toxicity. Hence,
decreased glutamate signalling could be beneﬁcial
for motor neuron survival in ALS.
Concluding remarks
During the past few years, several laboratories have
used gene-targeting techniques in mice to study the
functional roles ofall three VGLUTs, i.e.VGLUT1–3.
Our group has, together with others around the
world, focused on VGLUT2, the predominant iso-
form during embryonic development and in deep
brain structures, including the thalamus, in the adult.
Full knockout analyses revealed that VGLUT2 is
essential for life ex utero, as new-born pups die imme-
diately after birth due to dysfunctional respiratory
CPG. Using the conditional approach, VGLUT2
has been linked to normal function of the hypotha-
lamic regulation of feeding and maybe somewhat
more surprisingly, given the restricted distribution
of VGLUT2 in the cerebral cortex, to higher brain
function. These two studies, in which the Cre/LoxP
system was used, have given novel insights into
mechanisms that may be useful for the understanding
of human pathologies, in these cases diabetes and
schizophrenia-like behaviour. Also heterozygous
VGLUT2 mice have been analysed with the purpose
of addressing human conditions (both pain and epi-
lepsy have been addressed), and it has been shown
that VGLUT2 does play a role in mediating these
conditions. Further analyses will reveal more about
the mechanisms behind these ﬁndings. In a recent
study, a connection between VGLUT2 gene
expression and ALS was shown, which speciﬁed a
role for VGLUT2 in motor neuron survival.
The research ﬁeld of mouse genetics of the
VGLUTs is fairly new, and we expect that the next
few years will see a rapid development in this ﬁeld,
which will certainly give new insights into the
role of the different VGLUTs in glutamatergic
neurotransmission in the central nervous system.
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